Prosecution Insights
Last updated: November 04, 2026
Application No. 18/894,701

LIGAND-DRUG-CONJUGATE COMPRISING A SINGLE MOLECULAR WEIGHT POLYSARCOSINE

Non-Final OA §102§103§112
Filed
Sep 24, 2024
Priority
Oct 23, 2017 — EU 17306457.7 +3 more
Examiner
ROGERS, JAMES WILLIAM
Art Unit
1618
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Mablink Bioscience
OA Round
1 (Non-Final)
46%
Grant Probability
Moderate
1-2
OA Rounds
1y 9m
Est. Remaining
69%
With Interview

Examiner Intelligence

Grants 46% of resolved cases
46%
Career Allowance Rate
420 granted / 907 resolved
-13.7% vs TC avg
Strong +23% interview lift
Without
With
+22.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 10m
Avg Prosecution
49 currently pending
Career history
966
Total Applications
across all art units

Statute-Specific Performance

§101
0.7%
-39.3% vs TC avg
§103
42.5%
+2.5% vs TC avg
§102
22.2%
-17.8% vs TC avg
§112
23.9%
-16.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 907 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restriction Restriction to one of the following inventions is required under 35 U.S.C. 121: I. Claims 1,11,18-21 drawn to a ligand-drug conjugate, classified in A61K 47/6803. II. Claims 13 and 22-26 drawn to an intermediate drug compound, classified in A61P 35/00. The inventions are independent or distinct, each from the other because: Inventions I and II are related as mutually exclusive species in an intermediate-final product relationship. Distinctness is proven for claims in this relationship if the intermediate product is useful to make other than the final product, and the species are patentably distinct (MPEP § 806.05(j)). In the instant case, the intermediate product is deemed to be useful as an anticancer agent and the inventions are deemed patentably distinct because there is nothing of record to show them to be obvious variants. Restriction for examination purposes as indicated is proper because all the inventions listed in this action are independent or distinct for the reasons given above and there would be a serious search and/or examination burden if restriction were not required because one or more of the following reasons apply: The inventions require a different field of search (e.g., searching different classes/subclasses or electronic resources, or employing different search queries); and/or the prior art applicable to one invention would not likely be applicable to another invention. Applicant is advised that the reply to this requirement to be complete must include (i) an election of an invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention. The election of an invention may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable upon the elected invention. Should applicant traverse on the ground that the inventions are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103 or pre-AIA 35 U.S.C. 103(a) of the other invention. During a telephone conversation with Gabriel Magallanes on 10/13/2026 a provisional election was made without traverse to prosecute the invention of group I, claims 1,11,18-21. Affirmation of this election must be made by applicant in replying to this Office action. Claims 13 and 22-26 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected invention. The examiner has required restriction between product or apparatus claims and process claims. Where applicant elects claims directed to the product/apparatus, and all product/apparatus claims are subsequently found allowable, withdrawn process claims that include all the limitations of the allowable product/apparatus claims should be considered for rejoinder. All claims directed to a nonelected process invention must include all the limitations of an allowable product/apparatus claim for that process invention to be rejoined. In the event of rejoinder, the requirement for restriction between the product/apparatus claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product/apparatus are found allowable, an otherwise proper restriction requirement between product/apparatus claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product/apparatus claim will not be rejoined. See MPEP § 821.04. Additionally, in order for rejoinder to occur, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product/apparatus claims. Failure to do so may result in no rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1,11,18-21 rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. In particular the examiner did not find support in the specification as originally filed to claim Z is a spacer comprising a conjugated maleimide. While maleimide is described it is with respect to R groups, the examiner did not see support to claim Z is a conjugated maleimide. Claims 1,11,18-21 incorporate the new matter by dependency. Claims 1,11,18-19 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The recitation of "analog" found in claim 11 claim when referring to the type of drug renders the claim indefinite. The term “analog” is not defined by the claims, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. It is unclear what is encompassed and excluded by the limitation "analog”. A chemical analog could refer to either a structural or functional analog. A structural analog has a similar structure to another compound but varies by differing atoms and functional groups. A functional analog has similar physical properties but are different chemically. Hence, one of ordinary skill would clearly recognize that analogues of camptothecin claimed in claim 11, would read on any of those compounds having any widely varying groups that possibly substitute the compounds claimed. One of ordinary skill could not ascertain and interpret the metes and bounds of the patent protection desired as to these terms. Thus, it is unclear and indefinite as to how the “analogs” herein are encompassed thereby. Claims 1,11,18-21 incorporate the indefiniteness by dependency. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1,11,18-19 is/are rejected under 35 U.S.C. 102a1 as being anticipated by Tite et al. (WO 2013/050617), cited parent application 16/758,638. Tite discloses structured polypeptides including antibodies with loop sequences (meeting LIGAND) bound to sarcosine oligomers (meeting HPSMW), sarcosine polymers have hydroxyl as an end unit (meeting claim 19), the polysarcosine conjugate is then bound, including orthogonally, to various drugs and diagnostic agents including cytotoxic agents such as camptothecin, additionally other non-sarcosine linkers may be present between the ligand and drug, including non-natural amino acids (meeting claim 11) and maleimide (meeting Z). See entire disclosure including abstract, page 4 lines 6-21, page 5 lines 12-26, page 10 lines 1-3, lines 12-17 line 28-lage 11 line 10, page 13 lines 9-26, page 14 lines 21-27, page 15 lines 13-19, page 16 lines 3-7, page 17 lines 18-27. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claim(s) 1,11,18-21 is/are rejected under 35 U.S.C. 103 as being unpatentable over Tite et al. (WO 2013/050617) in view of Burke “Camptothecins in Cancer Therapy” 2005 Humana Press Inc, Ch. 14 pages 317-341, cited parent application, in view of Bala et al. “Prodrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38”, Journal of Controlled Release, Volume 172, Issue 1, 2013, Pages 48-61. Tite while teaching use of camptothecin as a drug is silent on the use of its analogue SN-38 and exatecan, as recited in claims 20-21. However, both SN-38 and exatecan were a well-known analogue of camptothecin as taught by Burke and Bala. Burke noted that exatecan was synthesized to exploit physicochemical features of camptothecins and increase therapeutic advantages compared to other analogues. See ¶ bridging pages 317 and 318. Burke notes interest is exatecan was increased when it showed much greater potency than camptothecin. Bala teaches that SN-38 was one of the most active analogs of camptothecin. See introduction. Since Tite already teaches use of camptothecin, the genus of drug to SN-38 and exatecan, one of ordinary skill in the art would have a high expectation of success in substituting them for the drug of the primary reference. Reason to make such a modification stems from the noted advantages of exatecan and SN-38 compared to camptothecin with regard to potency. Thus, the claimed invention would have been prima facie obvious since all the claimed elements were known in the prior art and one skilled in the art could have combined the elements as claimed by known methods with no change in their respective functions and the combination would have yielded predictable results to one of ordinary skill in the art at the time of the invention. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to JAMES W ROGERS whose telephone number is (571)272-7838. The examiner can normally be reached 9:30-6:00 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Hartley can be reached at 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JAMES W ROGERS/Primary Examiner, Art Unit 1618
Read full office action

Prosecution Timeline

Sep 24, 2024
Application Filed
Oct 16, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12779085
RADIOPAQUE POLYMERS
3y 3m to grant Granted Nov 03, 2026
Patent 12779054
LANTHANIDE COMPLEX FORMULATIONS
2y 3m to grant Granted Nov 03, 2026
Patent 12759047
Metal-based core nanoparticles, synthesis and use
4y 3m to grant Granted Oct 13, 2026
Patent 12758636
POLYTETRAFLUOROETHYLENE CO-POLYMER EMULSIONS
3y 6m to grant Granted Oct 13, 2026
Patent 12758658
DOUBLE-COMPONENT GASTRIC ULTRASOUND EXAMINATION AIDED DEVELOPER AND PREPARATION METHOD THEREFOR
2y 10m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
46%
Grant Probability
69%
With Interview (+22.6%)
3y 10m (~1y 9m remaining)
Median Time to Grant
Low
PTA Risk
Based on 907 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month